Dr Choo Su Pin
Medical Oncologist
BMedSci, BMBS(Nottm), MRCP(UK), FAMS (Medical Oncology)
Biography
Dr Choo Su Pin is a medical oncologist who specializes in gastrointestinal cancers including colorectal, upper gastrointestinal, pancreas, hepatobiliary, peritoneal, and anal cancers with more than 20 years of experience.
Prior to joining private practice, Dr Choo was the Deputy head of the division of medical oncology and Chief of the gastrointestinal cancer department at the National Cancer Centre Singapore (NCCS). She is currently a visiting consultant there.
Dr Choo graduated from the University of Nottingham Medical School, UK. She has fellowships from the Royal College of Physicians, UK and the Academy of Medicine, Singapore and was trained in medical oncology at NCCS. She was one of a few overseas participants selected to participate in the AACR/ASCO methods in cancer research workshop held in Vail. She also did a research fellowship at the University of California, San Francisco, USA where she worked on clinical trials for gastrointestinal cancers and undertook laboratory research on understanding neuroendocrine tumours. Dr Choo obtained a SMU-SingHealth graduate diploma in healthcare management and leadership.
At NCCS, she was a senior consultant in the division of medical oncology and co-director of the comprehensive liver cancer clinic. She was a driver of many initiatives and was instrumental in setting up the experimental cancer therapeutics unit at NCCS which focuses on drug development and early-phase oncology trials. She has led many clinical trials in gastrointestinal cancers and was deputy head of clinical trials and epidemiological sciences department of NCCS, before she became chair of the clinical trials steering committee.
Dr Choo also set up the gastrointestinal database at NCCS and was adjunct principal investigator at the SingHealth investigational medicine unit. She is a member of the Asia-Pacific hepatocellular cancer trials workgroup and was in the steering committee for the AHCC006 trial which was an international multicenter clinical trial on liver cancer led from Singapore. Research areas of particular interest include pancreatic-hepatobiliary cancers and immuno-oncology. She has received grant awards for her research work as principal investigator and as co-investigator.
She continues to use her experience in clinical research and currently serves as deputy chair of the SingHealth’s central institutional review board which oversees approval of oncology trials in the Singhealth network.
She has published in journals like Lancet, Nature Genetics, Journal of Clinical Oncology, Annals of Oncology and Cancer Discovery and has also presented her research work at numerous overseas meetings.
Besides her clinical work, Dr Choo is an adjunct associate professor, SingHealth Duke-NUS oncology academic clinic programme, Duke-NUS Medical School. She was an adjunct associate professor, department of medicine, Yong Loo Lin School of Medicine. She has also organised numerous oncology conferences including the Best of ASCO in Singapore, Asia-Pacific Liver Cancer Experts Meeting and the Asia-Pacific Gastroenterology Cancer Summit. She was the local chair of the European Society of Medical Oncology (ESMO) Asia conference in Singapore and co-chaired the ESMO preceptorship in gastrointestinal cancers.
Dr Choo serves as the Asst Bursar in the Academy of Medicine of Singapore where she is also the honorary secretary of the Chapter of Medical Oncology. She is currently a council member in the Singapore Cancer Society and chairs the Cancer Research committee and the Community Partnership committee while also being a member of the Community Health committee. She was the first female president of the Singapore Society of Oncology (SSO) and was the immediate past president. She is a founding member of the SSO-cancer immunotherapy consortium.
Internationally, Dr Choo has served on advisory boards of pharmaceutical companies for gastrointestinal cancer drug development, delivered lectures as an invited speaker at both national and international conferences. She continues to teach trainee oncologists and other oncologists in her field of GI cancers. She has also been involved in guideline development for cancers including hepatocellular carcinoma and pancreas cancer locally and in the Asia-Pacific region.
She is a faculty member for lower GI track in the European Society of Medical Oncology till 2025 and also serves as a member in the ESMO women for oncology committee, which advocates for women in the field of oncology.
She is a recipient of the Gold Excellence Service Award and the National Covid-19 Award in 2022.
Area of Interest
Gastrointestinal cancers
Curie Oncology Locations
Mount Elizabeth Novena Specialist Centre
Mount Elizabeth Medical Centre
Publications
Media
Rules on cancer treatment financing in Singapore can be improved | The Straits Times
Private hospitals facing bed crunch, lack of manpower to keep all wards open | The Straits Times
Oncoshot Enters Into MOU With Singapore Clinical Research Institute
Liver cancer top cause of cancer death among men in their 40s and 50s
Immunotherapy for Hepatocellular Carcinoma
Colorectal Cancer – Doctor Q&A
Influence: Dr Choo Su Pin, Singapore Society of Oncology
New two-pronged method to fight deadly liver cancer
Liver cancer patients wanted for new clinical trial
Learning more about Liver Cancer
Dr Choo Su Pin – I run for my cancer patients
Medical experts in Singapore combine two treatments to treat liver cancer
Dr Choo Su Pin on ongoing Phase III EMERALD-1 study for cancer patients with intermediate stage HCC
The Daily Star: Dr Choo Su Pin enlightens on Gastrointestinal Cancers
Singapore study introduces new strategy to treat advanced liver cancer
Clinical Trials
–
Clinical Trials
No. | Tumor Type | Stage | Study Title | Principal Investigator | Details | Status |
---|---|---|---|---|---|---|
1 | Lung Cancer | IV | A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer | Dr Toh Chee Keong | #NCT04262856 | Open |
2 | Breast cancer | IV | A Randomized, multicentre, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of ER(+), HER(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease | Dr Lynette Ngo | #NCT04478266 | Open |
3 | Hepatocellular carcinoma | IV | A Phase III, Randomized Double-blind, Placebo-controlled, Multicentre Study of Transarterial Chemoembolization (TACE) in Combination With either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) | Dr Choo Su Pin | #NCT03778957 Emerald-1 Trial Patient Information | Open |
4 | Endometrial cancer | IV | A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer(DUO-E) | Dr Lynette Ngo | #NCT04269200 | Open |
5 | Gastric cancer | IV | A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer | Dr Choo Su Pin | #NCT04139135 | Closed |